Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. grew its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 48.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 504,835 shares of the biopharmaceutical company's stock after purchasing an additional 165,440 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.08% of Royalty Pharma worth $14,282,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Xponance Inc. increased its holdings in Royalty Pharma by 1.9% during the second quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company's stock valued at $836,000 after buying an additional 606 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Royalty Pharma by 32.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 655 shares in the last quarter. Values First Advisors Inc. grew its stake in Royalty Pharma by 7.6% in the third quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company's stock valued at $295,000 after purchasing an additional 738 shares during the last quarter. Phillips Wealth Planners LLC boosted its holdings in shares of Royalty Pharma by 10.2% in the 3rd quarter. Phillips Wealth Planners LLC now owns 8,733 shares of the biopharmaceutical company's stock valued at $246,000 after buying an additional 808 shares in the last quarter. Finally, Meeder Advisory Services Inc. grew its holdings in Royalty Pharma by 12.7% in the second quarter. Meeder Advisory Services Inc. now owns 8,223 shares of the biopharmaceutical company's stock worth $217,000 after purchasing an additional 926 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. StockNews.com raised Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Tuesday. Citigroup dropped their price target on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday, October 25th. Morgan Stanley increased their price objective on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an "overweight" rating in a research report on Thursday, July 11th. Finally, The Goldman Sachs Group boosted their target price on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a "buy" rating in a research report on Wednesday, August 14th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $41.67.

Royalty Pharma Stock Performance

NASDAQ RPRX traded down $0.13 during trading hours on Thursday, reaching $26.51. The stock had a trading volume of 1,584,840 shares, compared to its average volume of 2,568,176. Royalty Pharma plc has a 52-week low of $25.20 and a 52-week high of $31.66. The stock has a fifty day moving average of $27.88 and a 200 day moving average of $27.55. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35. The stock has a market cap of $15.73 billion, a P/E ratio of 23.46, a price-to-earnings-growth ratio of 4.00 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping analysts' consensus estimates of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The firm had revenue of $537.00 million for the quarter, compared to analyst estimates of $600.83 million. During the same quarter in the prior year, the business earned $0.85 earnings per share. Sell-side analysts predict that Royalty Pharma plc will post 4.05 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.21 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.17%. Royalty Pharma's payout ratio is 74.34%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.